Carrier-free nanomedicines for cancer treatment. (April 2022)

• Record Type: Journal Article
• Authors: Liu, Li-Han; Zhang, Xian-Zheng
• Is Part Of: Progress in materials science. Volume 125(2022)
• Publication Date: 2022-04
• Subjects: Carrier-free -- Self assembly -- Nanomedicine -- Prodrug -- Tumor therapy; DDSs Drug delivery systems -- FDA Food and Drug Administration -- EPR Enhanced permeation and retention -- PNDs Pure nanodrugs -- NCs Nanocrystals -- CPT Camptothecin -- HCPT Hydroxycamptothecin -- PTX Paclitaxel -- UA Ursolic acid -- MDR Multidrug resistance -- TPGS D-R-tocopheryl polyethylene glycol 1000 succinate -- P-gp P-glycoprotein -- NSs Nanospheres -- NRs Nanorods -- PDT Photodynamic therapy -- PSs, PS Photosensitizers -- HPPH 2-devinyl-2-(1-hexyloxyethyl)pyropheophorbide -- COX-2 Cyclooxygenase-2 -- Ind, IDM Indomethacin -- Cur Curcumin -- DOX Doxorubicin -- AAO Anodized aluminum oxide -- VM-26 Teniposide -- 6-MP 6-Mercaptopurine -- BCNU Carmustine -- TMF Tamoxifen -- MTX Methotrexate -- H2TPyP 5, 10, 15, 20-tetro(4-pyridyl)porphyrin -- PTT Photothermal therapy -- PTAs Photothermal agents -- DiR 1, 1′-dioctadecyl-3, 3, 3′, 3′-tetramethylindotricarbocyanine iodide -- ROS Reactive oxygen radicals -- AIE Aggregation-induced emission -- ACQ Aggregation-caused quenching -- ATP Adenosine triphosphate -- YSV Tyroservatides -- GEF Gefitinibs -- RT Raltitrexed -- CA Clofarabine -- BODIPY Borondipyrromethene -- CCCMs Cracked cancer cell membranes -- PA Phytic acid -- CRT 7-nitroindole-2-carboxylic acid -- TA Tannic acid -- ICG Indocyanine green -- AuTPyP Au(III) tetra-(4-pyridyl) porphine -- PD-L1 Programmed cell death ligand 1 -- PD-1 Programmed death 1 -- ICIs Immune checkpoint inhibitors -- Met Metformin -- HDAC Histone deacetylase -- SAHA Vorinostat -- α-TOS α-tocopherol succinate -- Ce6 Chlorin e6 -- BER Base excision repair -- ATO Atovaquone -- GSH Glutathione -- CPG Clopidogrel -- PPa Pyropheophorbide a -- ICD Immunogenetic cell death -- DCs Dendritic cells -- CTLs Cytotoxic T lymphocytes -- IDO-1 Indoleamine 2, 3-dioxygenase 1 -- ITM Immunosuppressive tumor microenvironment -- Tregs Regulatory T cells -- TNBC Triple negative breast cancer -- CDT Chemodynamic therapy -- GPX4 GSH peroxide 4 -- FRET Fluorescence resonance energy transfer -- TPE Tetraphenylethylene -- PcS Phthalocyanine -- MA Mitoxantrone -- PDI Perylene diimide -- PFC Perfluorocarbon -- NIRF Near-infrared fluorescence -- PA Photoacoustic -- EPI Epirubicin -- QSNAP Quantitative structure-nanoparticle assembly prediction -- Fmoc-L-L 9-fluorenylmethyloxycarbonyl-L-Leucine -- MRI Magnetic resonance imaging -- Fmoc-H Fluorenylmethoxycarbonyl-L-histidine -- Z-HF N-benzyloxycarbonyl-L-histidine-L-phenylalanine -- BV Biliverdin -- ZHO Z-Histidine-Obzl -- PAI Photoacoustic imaging -- DVDMS Sinoporphyrin sodium -- TVECs Tumor vascular endothelial cells -- PpIX Protoporphyrin IX -- BSO L-buthionine sulfoximine -- ZnPP Protoporphyrin zinc(II) -- ART Artemisinin -- ZOL Zoledronate -- Cu Copper -- Gd Gadolinium -- RB Rose Bengal -- RT Radiation therapy -- TME tumor microenvironment -- S-siRNA Survivin-small-interfering RNA -- HSP70 Heat shock protein 70 -- TCPP Tetrakis(4-carboxyphenyl) porphyrin -- CpG Cytosine-phosphorothioate-guanine -- MONCs Metal-organic nanodrug complexes -- DNA Deoxyribonucleic acid -- Bcl-2 B-cell lymphoma 2 -- MC Minocycline -- HAS Human serum albumins -- mTHPP 5, 10, 15, 20-tetrakis(m-hydroxyphenyl)porphyrine -- mTHPC 5, 10, 15, 20-tertrakis(m-hydroxyphenyl)chlorin -- BSA Bovine serum albumin -- DTPA Diethylenetriamine pentaacetic acid -- GGD Gadolinium (III)-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetate -- GA Gambogic acid -- HSP90 Heat shock protein 90 -- ICB Immune checkpoint blockade -- PFS Progression-free survival -- DAS Dasatinib -- PPT Podophyllotoxin -- Ir Irinotecan -- Bd Bendamustine -- TOS D-α-tocopherol succinate -- DCA Dichloroacetic acid -- F, FUDR Floxuridine -- TMP Tetramethylpyrazine -- ELT Erlotinib -- HUVECs Human umbilical vein endothelial cells -- ALA 5-aminolevulinic acid -- CDDP Cisplatin -- CP Cyclopamine -- CA4 Combretastatin A-4 -- EET Electronic energy transfer -- PET Positron emission tomography -- SMPA Small molecule prodrug-amphiphiles -- SQ Squalenic acid -- OFZG 1-O-octadecyl-2-(5-fluorouracil)-N-acetyl-3-zidovudine- phosphorylglycerol -- NOG N-octadecanoyl gemcitabine -- Ara-C Cytarabine -- HA Hexanoic acid -- OEG Oligo(ethylene glycol) -- RA Retinoic acid -- CIT Citronellol -- ASGPR Asialoglycoprotein receptor -- EB Evans blue -- WP6 Water-soluble pillar[6]arenes -- CDs Cyclodextrins -- PEG-b-PLA Poly(ethylene glycol)-b-poly(L-lactide) -- PEG-b-PCL Poly(ethylene glycol)-b-poly(Ɛ-caprolactone) -- PEG-b-P(LA-co-MCC) Poly(ethylene glycol)-b-poly(2-methyl-2-carboxyl-propylene carbonate) -- PEG-b-PG2MA Poly(ethylene glycol)-b-poly(glycerol monomethacrylate) -- PEO-b-P(BMA-co-CMA) Poly(ethyleneoxide)-b-poly(n-butylMethacrylate-co-4-methyl-[7-(methacryloyl)oxyethyloxy]coumarin)) -- 5-FU 5-Fluorouracil -- PEG-b-PHAA Poly(ethylene glycol)-b-poly(2-hydroxyethyl aspartamide) -- PEG-PLGA Poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) -- PHEA Poly(2-hydroxyethyl-L-aspartamide) -- CR Cerenkov radiation -- PHS Phytosphingosine -- PG Poly-α-(L-glutamic acid) -- PGG–PTX Poly(L-γ-glutamylglutamine)-paclitaxel -- HPMA [N-(2-hydroxypropyl)methacrylamide] -- Dtxl Docetaxel -- PLA Polylactide -- PFA Poly(ferulic acid) -- PUA Poly(ursolic acid) -- PVO Poly(vanillin oxalate) -- PEO Poly(ethylene oxide) -- MPS 3-(trimethoxysilyl)propyl methacrylate -- GCVs Polyprodrug-gated crosslinked vesicles -- PDCs Peptide-drug conjugates -- DA Drug amphiphile -- buSS Disulfylbutyrate -- Cap Capecitabine -- FA Folate acid -- MMP2 Matrix metalloproteinases 2 -- DMA 2, 3-dimethylmaleic anhydride -- 1MT 1-methyl-tryptophan -- PFTase Protein farnesyltransferase -- DAMPs Damage associated molecular patterns -- PNI Photodynamic nanoinhibitors -- EISA Enzyme-instructed self-assembly -- AIR Assembly induced retention -- CBT 1, 2-aminothiol and 2-cyanobenzothiazole -- Olsa Olsalazine -- CEST MRI Chemical exchange saturation transfer magnetic resonance imaging -- Amp 4-amino-proline -- TMAS Tumor microenvironment-adaptable self-assembly -- NADC Nucleic acid-drug conjugates -- T Thymine -- ASOs Antisense oligonucleotides -- SNA Spherical nucleic acid -- DTM Dithiomaleimide -- DCgC Drug-chemogene conjugate -- HDPs Host defense peptides -- ACPP Anticancer cationic peptide -- DA 2, 3-dimethylmaleic anhydride -- CES Carboxylesterase -- ALP Alkaline phosphatase -- TPP Triphenyl phosphinium -- ER Endoplasmic reticulum -- MMP7 Matrix metalloproteinase 7 -- β-Gal β-galactosidase -- CAC Critical aggregation concentration -- OLISA Organelle localization induced supramolecular self-assembly -- HER2 Human epidermal growth factor receptor 2 -- BP Bis-pyrene -- Aβ Amyloid β -- CARPA Complement activation-related pseudoallergy; Materials science -- Periodicals; Science des matériaux -- Périodiques; 620.1105
• DOI: 10.1016/j.pmatsci.2021.100919
• Languages: English
• ISSNs: 0079-6425

Abstract

Abstract: The last decade witnessed the great advances in the development of nanomedicines. As a kind of attractive nanomedicine, carrier-free nanomedicines received extensive investigations because of their high biosafety, high drug loading capacities, simple drug compositions and simplified synthetic procedures. Extensive efforts have been made to exploit more excipients and therapeutic agents, new self-assembly methods and therapeutic mechanisms to expand the scope of carrier-free nanomedicines with enhanced therapeutic performance. In this review, we summarized the research progress of carrier-free nanomedicines with practical applications in cancer therapy. Carrier-free nanomedicines were classified into three kinds, including free drugs, prodrugs and non-drug agents based carrier-free nanomedicines. These carrier-free nanomedicines were introduced in detail according to their drug compositions, assembly and antitumor applications. The current clinical translation situation and safety of carrier-free nanomedicines were also summarized. The outlooks were included in the conclusion section to discuss the existing challenges on the future development and clinical application of carrier-free nanomedicines.